Skip to main content
. 2021 Feb 10;11(2):e042384. doi: 10.1136/bmjopen-2020-042384

Table 1.

Main characteristics of studies included in the meta-analysis

First author/year Region Group Patients
/eyes (n)
GA (weeks)
(mean±SD)
BW (g) (mean±SD) Follow-up
(months)
Type of
anti-VEGF
Anti-VEGF dose (mg) NOS score
Harder 201318 Germany Anti-VEGF laser 12/23
13/26
25.20±1.60
25.30±1.80
622.00±153.00
717.00±197.00
12 Bevacizumab 0.375 or 0.625 7
Hwang 201519 American Anti-VEGF laser 11/22
17/32
NA 668.10±127.30
701.40±118.80
21.7
32.5
Bevacizumab 0.625 8
Kabatas11 2017* Turkey Anti-VEGF laser 12/24
36/72
26.10±2.27
27.70±2.70
841.00±235.00
1112.00±362.00
18 Bevacizumab 0.625 8
Kabatas11 2017* Turkey Anti-VEGF laser 6/12
36/72
26.00±1.26
27.70±2.70
840.00±177.00
1112.00±362.00
18 Ranibizumab 0.25 8
Kuo 201520 Taiwan Anti-VEGF laser 15/15
14/14
27.33±2.94
27.43±2.93
1079.67±357.48
1006.79±327.65
3 years of age Bevacizumab 0.5 7
Kang 201921 Korea Anti-VEGF laser 12/22
15/30
27.40±2.00
34.00±2.90
983.20±265.60
961.00±286.50
4 years of age Bevacizumab ranibizumab 0.625
0.2
7
Isaac 201522 Canada Anti-VEGF laser 13/23
12/22
25.20±1.40
25.00±1.10
722.00±131.00
674.00±175.00
16.00±6.00
6.00±3.00
Bevacizumab 0.625 8
Vujanović 201723 Serbia Anti-VEGF laser 21/42
45/90
29.00±4.00
30.00±4.00
1175.00±425.00
1200.00±500.00
9 Bevacizumab 0.625 8
Gunay 201624* Turkey Anti-VEGF laser 55/107
57/113
27.31±2.18
28.23±2.50
1005.29±411.19
1119.47±336.96
19.40±6.43
20.68±6.89
Bevacizumab 0.625 8
Gunay 201624* Turkey Anti-VEGF laser 22/44
57/113
27.95±2.90
28.23±2.50
1195.90±466.98
1119.47±336.96
18.96±4.79
20.68±6.89
Ranibizumab 0.25 8
Chen 201925 Taiwan Anti-VEGF laser 13/25
12/22
26.46±1.51
25.50±1.24
862.54±197.65
815.83±151.07
NA Bevacizumab 0.625 7
Lee 201826 Taiwan Anti-VEGF laser 17/33
13/24
26.60±1.60
26.60±2.50
874.10±228.70
803.10±144.90
>48 Bevacizumab 0.625 6
Roohipoor 201827 Iran Anti-VEGF laser NA/397
NA/190
27.8 1146 >12 Bevacizumab 0.625 8
Geloneck 201416 American Anti-VEGF laser 56/110
53/101
24.3 625 2.5 years of age Bevacizumab 0.625 8
O‘Keeffe 201617 lrish Anti-VEGF laser 15/15
15/15
25±1.25 780±135 60 Bevacizumab 1.25 6

*There are two types of antivascular endothelial growth factor (VEGF) drugs included in the literature, so the details are listed separately.

BW, birth weight; GA, gestational age; NA, not applicable; NOS, Newcastle-Ottawa Scale; RCT, randomised controlled trial.